Neuroimmune crosstalk in CNS disorders: The histamine connection

Current Pharmaceutical Design

Volumn 22, Issue 7, 2016, Pages 819-848

  Cacabelos, Ramón ^a,b,c   Torrellas, Clara ^a,b   Fernández Novoa, Lucía ^c   Aliev, Gjumrakch ^d,e,f  

^a CAMILO JOSÉ CELA UNIVERSITY   (Spain)

^b Centro de Investigacion Biomedica EuroEspes   (Spain)

^c EuroEspes Biotechnology   (Spain)

^d University of Atlanta   (United States)

^e INSTITUTE OF PHYSIOLOGICALLY ACTIVE COMPOUNDS   (Russian Federation)

^f GALLY International Biomedical Research Consulting LLC   (United States)

Author keywords

Alzheimer s disease; CNS disorders; Genomics; Histamine; Immune markers; Neuroimmune system

Indexed keywords

CHEMOKINE RECEPTOR CCR3; CXCL9 CHEMOKINE; EOTAXIN; EOTAXIN 2; FRACTALKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUCOCORTICOID; HISTAMINE; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; IBUPROFEN; ICOSANOID; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 10; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; KYNURENINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MIRTAZAPINE; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHOPROTEIN DARPP 32; TUMOR NECROSIS FACTOR ALPHA;

AGE RELATED MACULAR DEGENERATION; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; DEPRESSION; ENCEPHALITIS; EPILEPSY; GENE FREQUENCY; GLIA CELL; HEREDITY; HIV ASSOCIATED DEMENTIA; HUMAN; HUNTINGTON CHOREA; IMMUNOGLOBULIN PRODUCTION; IMMUNOPATHOGENESIS; MAST CELL; MENTAL DEFICIENCY; MIGRAINE; MULTIINFARCT DEMENTIA; MULTIPLE SCLEROSIS; NONHUMAN; PARKINSON DISEASE; PRION DISEASE; PRIORITY JOURNAL; SCHIZOPHRENIA; TAUOPATHY; TRAUMATIC BRAIN INJURY; AGE; ANIMAL; CENTRAL NERVOUS SYSTEM; DISEASE COURSE; IMMUNOLOGY; IMMUNOMODULATION; PATHOPHYSIOLOGY; PHYSIOLOGY; SEX DIFFERENCE;

AGE FACTORS; ANIMALS; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; DISEASE PROGRESSION; HISTAMINE; HUMANS; NEUROIMMUNOMODULATION; SEX FACTORS;

EID: 84958555131     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666151209150954     Document Type: Article

References (239)

1. Cotman CW, Brinton RE, Galaburda A, McEwen B, Schneider DM, Eds. The Neuro-Immune-Endocrine Connection. New York: Raven Press 1987.
2. Goetzl EJ, Spector NH, Eds. Neuroimmune Networks: Physiology and Diseases. New York: Alan R Liss 1989.
3. Ader R, Felten DL, Cohen N, Eds. Psychoneuroimmunology. San Diego: Academic Press 1991.
4. Baxter A, Ross R. Cytokine interactions and their control. Chichester: Wiley 1991.
5. Husband AJ, Ed. Behaviour and Immunity. Boca Raton: CRC Press 1992.
6. Théze J, Ed. The cytokine network and immune functions. Oxford: Oxford University Press 1999.
7. Chang RC, Chiu K, Ho YS, So KF. Modulation of neuroimmune responses on glia in the central nervous system: implication in therapeutic intervention against neuroinflammation. Cell Mol Immunol 2009; 6: 317-26.
8. Hosoi T, Okuma Y, Nomura Y. The mechanisms of immune-tobrain communication in inflammation as a drug target. Curr Drug Targets Inflamm Allergy 2002; 1: 257-62.
9. Banks WA, Erickson MA. The blood-brain barrier and immune function and dysfunction. Neurobiol Dis 2010; 37: 26-32.
10. Banks WA. The blood-brain barrier in psychoneuroimmunology. Immunol Allergy Clin North Am 2009; 29: 223-8.
11. Verma S, Nakaoke R, Dohgu S, Banks WA. Release of cytokines by brain endothelial cells: A polarized response to lipopolysaccharide. Brain Behav Immun 2006; 20: 449-55.
12. Vojdani A, Lambert J. The role of Th17 in neuroimmune disorders: Target for CAM therapy. Part II. Evid Based Complement Alternat Med 2011; 2011: 548086.
13. Catania A, Lonati C, Sordi A, Gatti S. Detrimental consequences of brain injury on peripheral cells. Brain Behav Immun 2009; 23: 877-84.
14. Rettori V, Fernández-Solari J, Mohn C, et al. Nitric oxide at the crossroad of immunoneuroendocrine interactions. Ann NY Acad Sci 2009; 1153: 35-47.
15. Coogan AN, Wyse CA. Neuroimmunology of the circadian clock. Brain Res 2008; 1232: 104-12.
16. Ben Achour S, Pascual O. Glia: The many ways to modulate synaptic plasticity. Neurochem Int 2010; 57: 440-5.
17. Brynskikh A, Warren T, Zhu J, Kipnis J. Adaptive immunity affects learning behavior in mice. Brain Behav Immun 2008; 22: 861-9.
18. Anderson CNG, Grant SGN. High throughput protein expression screening in the nervous system-needs and limitations. J Physiol 2006; 575: 367-72.
19. Xu X, Zhan M, Duan W, et al. Gene expression atlas of the mouse central nervous system: impact and interactions of age, energy intake and gender. Genome Biol 2007; 8: R234.
20. Schafer DP, Stevens B. Synapse elimination during development and disease: immune molecules take centre stage. Biochem Soc Trans 2010; 38: 476-81.
21. Dorban G, Defaweux V, Heinen E, Antoine N. Spreading of prions from the immune to the peripheral nervous system: a potential implication of dendritic cells. Histochem Cell Biol 2010; 133: 493-504.
22. Glanzer JG, Enose Y, Wang T, et al. Genomic and proteomic microglial profiling: pathways for neuroprotective inflammatory responses following nerve fragment clearance and activation. J Neurochem 2007; 102: 627-45.
23. Licinio J, Mastronardi C, Wong ML. Pharmacogenomics of neuroimmune interactions in human psychiatric disorders. Exp Physiol 2007; 92: 807-11.
24. Cacabelos R, Martínez-Bouza R. Genomics and pharmacogenomics of schizophrenia. CNS Neurosci Ther 2011; 17: 541-65.
25. Cacabelos R, Fernández-Novoa L, Lombardi V, et al. Genomics of schizophrenia and psychotic disorders. Gen-T (EuroEspes J Int Ed) 2011; 3: 6-86.
26. Cacabelos R, Cacabelos P, Aliev G. Genomics and pharmacogenomics of antipsychotic drugs. Open J Psychiatr 2013; 3: 46-139.
27. Carter CJ. Schizophrenia susceptibility genes directly implicated in the life cycles of pathogens: cytomegalovirus, influenza, herpes simplex, rubella, and Toxoplasma gondii. Schizophr Bull 2009; 35: 1163-82.
28. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull 2009; 35: 549-62.
29. Lang UE, Puls I, Muller DJ, Strutz-Seebohm N, Gallinat J. Molecular mechanisms of schizophrenia. Cell Physiol Biochem 2007; 20: 687-702.
30. Bennett M. Positive and negative symptoms in schizophrenia: the NMDA receptor hypofunction hypothesis, neuregulin/ErbB4 and synapse regression. Aust N Z J Psychiatry 2009; 43: 711-21.
31. Fatemi SH, Folsom TD. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr Bull 2009; 35: 528-48.
32. Saetre P, Emilsson L, Axelsson E, Kreuger J, Lindholm E, Jazin E. Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry 2007; 7: 46.
33. Arion D, Unger T, Lewis DA, Levitt P, Mirnics K. Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. Biol Psychiatry 2007; 62: 711-21.
34. Hanson DR, Gottesman II. Theories of schizophrenia: a geneticinflammatory-vascular synthesis. BMC Med Genet 2005; 6: 7.
35. Dean B. Is schizophrenia the price of human central nervous system complexity? Aust N Z J Psychiatry 2009; 43: 13-24.
36. Bilbo SD, Schwarz JM. Early-life programming of later-life brain and behaviour: a critical role for the immune system. Front Behav Neurosci 2009; 3: 1-14.
37. Meyer U, Feldon J. Prenatal exposure to infection: a primary mechanism for abnormal dopaminergic development in schizophrenia. Psychopharmacology (Berl) 2009; 206: 587-602.
38. Kinney DK, Hintz K, Shearer EM, et al. A unifying hypothesis of schizophrenia: abnormal immune system development may help explain roles of prenatal hazards, post-pubertal onset, stress, genes, climate, infections, and brain dysfunction. Med Hypotheses 2010; 74: 555-63.
39. Brown AS, Derkits EJ. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 2010; 167: 261-80.
40. Boksa P. Effects of prenatal infection on brain development and behavior: A review of findings from animal models. Brain Behav Immun 2010; 24: 881-97.
41. Ito HT, Smith SE, Hsiao E, Patterson PH. Maternal immune activation alters nonspatial information processing in the hippocampus of the adult offspring. Brain Behav Immun 2010; 24: 930-41.
42. Bitanihirwe BK, Weber L, Feldon J, Meyer U. Cognitive impairment following prenatal immune challenge in mice correlates with prefrontal cortical AKT1 deficiency. Int J Neuropsychopharmacol 2010; 13: 981-96.
43. Feleder C, Tseng KY, Calhoon GG, O'Donnell P. Neonatal intrahippocampal immune challenge alters dopamine modulation of prefrontal cortical interneurons in adult rats. Biol Psychiatry 2010; 67: 386-92.
44. Chubb JE, Bradshaw NJ, Soares DC, et al. The DISC locus in psychiatric illness. Mol Psychiatry 2008; 13: 36-64.
45. Nakata K, Lipska BK, Hyde TM, et al. DISC1 splice variants are upregulated in schizophrenia and associated with risk polymorphisms. Proc Natl Acad Sci USA 2009; 106: 15873-8.
46. Crepel A, Breckpot J, Fryns JP, et al. DISC1 duplication in two brothers with autism and mild mental retardation. Clin Genet 2010; 77: 389-94.
47. Enomoto A, Asai N, Namba T, et al. Roles of disrupted-inschizophrenia 1-interacting protein girdin in postnatal development of the dentate gyrus. Neuron 2009; 63: 774-87.
48. Kim JY, Duan X, Liu CY, et al. DISC1 regulates new neuron development in the adult brain via modulation of AKT-mTOR signaling through KIAA1212. Neuron 2009; 63: 761-73.
49. Matsuzaki S, Tohyama M. Molecular mechanism of schizophrenia with reference to disrupted-in-schizophrenia 1 (DISC1). Neurochem Int 2007; 51: 165-72.
50. Millar JK, Mackie S, Clapcote SJ, et al. Disrupted in schizophrenia 1 and phosphodiesterase 4B: towards an understanding of psychiatric illness. J Physiol 2007; 584: 401-5.
51. Bradshaw NJ, Ogawa F, Antolin-Fontes B, et al. DISC1, PDE4B, and NDE1 at the centrosome and synapse. Biochem Biophys Res Commun 2008; 377: 1091-6.
52. Tomppo L, Hennah W, Lahermo P, et al. Association between genes of Disrupted in schizophrenia 1 (DISC1) interactors and schizophrenia supports the role of the DISC1 pathway in the etiology of major mental illnesses. Biol Psychiatry 2009; 65: 1055-62.
53. Drerup CM, Wiora HM, Topczewski J, Morris JA. Disc1 regulates foxd3 and sox10 expression, affecting neural crest migration and differentiation. Development 2009; 136: 2623-32.
54. Takahashi T, Suzuki M, Tsunoda M, et al. The Disrupted-in-Schizophrenia-1 Ser704Cys polymorphism and brain morphology in schizophrenia. Psychiatry Res 2009; 172: 128-35.
55. Schumacher J, Laje G, Abou Jamra R, et al. The DISC locus and schizophrenia: evidence from an association study in a central European sample and from a meta-analysis across different European populations. Human Mol Genet 2009; 18: 2719-27.
56. Ibi D, Nagai T, Koike H, et al. Combined effect of neonatal immune activation and mutant DISC1 on phenotypic changes in adulthood. Behav Brain Res 2010; 206: 32-7.
57. Frezza D, Giambra V, Mattioli C, et al. Allelic frequencies of 3' Ig heavy chain locus enhancer HS1, 2-A associated with Ig levels in patients with schizophrenia. Int J Immunopathol Pharmacol 2009; 22: 115-23.
58. Halacheva K, Dimova S, Tolev T, Dimov D, Nikolova M. Elevated anticardiolipin antibodies in schizophrenic patients before and during neuroleptic medication. Psychiatry Res 2009; 169: 51-5.
59. Chittiprol S, Venkatasubramanian G, Neelakantachar N, Reddy NA, Shetty KT, Gangadhar BN. Longitudinal study of beta2-microglobulin abnormalities in schizophrenia. Int Immunopharmacol 2009; 9: 1215-7.
60. Chandley MJ, Miller MN, Kwasigroch CN, Wilson TD, Miller BE. Increased antibodies for the alpha7 subunit of the nicotinic receptor in schizophrenia. Schizophr Res 2009; 109: 98-101.
61. Laske C, Zank M, Klein R, et al. Autoantibody reactivity in serum of patients with major depression, schizophrenia and healthy controls. Psychiatry Res 2008; 158: 83-6.
62. Torres KC, Souza BR, Miranda DM, et al. The leukocytes expressing DARPP-32 are reduced in patients with schizophrenia and bipolardisorder. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 214-9.
63. Torres KC, Souza BR, Miranda DM, et al. Expression of neuronal calcium sensor-1 (NCS-1) is decreased in leukocytes of schizophrenia and bipolar disorder patients. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 229-34.
64. Herberth M, Krzyszton DN, Koethe D, et al. Differential effects on T-cell function following exposure to serum from schizophrenia smokers. Mol Psychiatry 2010; 15: 364-71.
65. Mayilyan KR, Weinberger DR, Sim RB. The complement system in schizophrenia. Drug News Perspect 2008; 21: 200-10.
66. Sun S, Wei J, Li H, et al. A family-based study of the IL3RA gene on susceptibility to schizophrenia in a Chinese Han population. Brain Res 2009; 1268: 13-6.
67. Schwarz MJ, Krönig H, Riedel M, et al. IL-2 and IL-4 polymorphisms as candidate genes in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2006; 256: 72-6.
68. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008; 63: 801-8.
69. Na KS, Kim YK. Monocytic, Th1 and Th2 cytokine alterations in the pathophysiology of schizophrenia. Neuropsychobiology 2007; 56: 55-63.
70. Bresee C, Rapaport MH. Persistently increased serum soluble interleukin-2 receptors in continuously ill patients with schizophrenia. Int J Neuropsychopharmacol 2009; 12: 861-5.
71. Singh B, Bera NK, Nayak CR, Chaudhuri TK. Decreased serum levels of interleukin-2 and interleukin-6 in Indian Bengalee schizophrenic patients. Cytokine 2009; 47: 1-5.
72. Schmitt A, Bertsch T, Tost H, et al. Increased serum interleukin-1beta and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication. Neuropsychiatr Dis Treat 2005; 1: 171-7.
73. Zhang XY, Zhou DF, Qi LY, et al. Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics. Psychopharmacology (Berl) 2009; 204: 177-84.
74. Yu L, Yang MS, Zhao J, et al. An association between polymorphisms of the interleukin-10 gene promoter and schizophrenia in the Chinese population. Schizophr Res 2004; 71: 179-83.
75. Ozbey U, Tug E, Namli M. Interleukin-10 gene promoter polymorphism in patients with schizophrenia in a region of East Turkey. World J Biol Psychiatry 2009; 10: 461-8.
76. Schosser A, Aschauer HN, Wildenauer DB, et al. Homozygosity of the interleukin-10 receptor 1 G330R allele is associated with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2007; 144: 347-50.
77. Ozbey U, Tug E, Kara M, Namli M. The value of interleukin-12B (p40) gene promoter polymorphism in patients with schizophrenia in a region of East Turkey. Psychiatr Clin Neurosci 2008; 62: 307-12.
78. Zai G, Müller DJ, Volavka J, et al. Family and case-control association study of the tumor necrosis factor-alpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication. Psychopharmacology (Berl) 2006: 188: 171-82.
79. Czerski PM, Rybakowski F, Kapelski P, et al. Association of tumor necrosis factor-308G/A promoter polymorphism with schizophrenia and bipolar affective disorder in a Polish population. Neuropsychobiology 2008; 57: 88-94.
80. Mundo E, Altamura AC, Vismara S, et al. MCP-1 gene (SCYA2) and schizophrenia: a case-control association study. Am J Med Genet B Neuropsychiatr Genet 2005; 132: 1-4.
81. Rapaport MH, Bresee C. Serial mitogen-stimulated cytokine production from continuously ill patients with schizophrenia. Neuropsychopharmacology 2010; 35: 428-34.
82. Sugino H, Futamura T, Mitsumoto Y, Maeda K, Marunaka Y. Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 303-7.
83. Behrens MM, Ali SS, Dugan LL. Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia. J Neurosci 2008; 28: 13957-66.
84. Teixeira AL, Reis HJ, Nicolato R, et al. Increased serum levels of CCL11/eotaxin in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 710-4.
85. Rasmussen HB, Timm S, Wang AG, et al. Association between the CCR5 32-bp deletion allele and late onset of schizophrenia. Am J Psychiatry 2006; 163: 507-11.
86. International Schizophrenia Consortium. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 2008; 455: 237-41.
87. Stefansson H, Ophoff RA, Steinberg S, et al. Common variants conferring risk of schizophrenia. Nature 2009; 460: 744-7.
88. Müller N. COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. Curr Opin Investig Drugs 2010; 11: 31-42.
89. Cui K, Ashdown H, Luheshi GN, Boksa P. Effects of prenatal immune activation on hippocampal neurogenesis in the rat. Schizophr Res 2009; 113: 288-97.
90. Bernstein HG, Steiner J, Bogerts B. Glial cells in schizophrenia: Pathophysiological significance and possible consequences for therapy. Expert Rev Neurother 2009; 9: 1059-71.
91. Cox D, Chan MK, Bahn S. The potential of immune biomarkers to advance personalized medicine approaches for schizophrenia. J Nerv Ment Dis 2015; 203: 393-9.
92. Sperner-Unterweger B, Fuchs D. Schizophrenia and psychoneuroimmunology: An integrative view. Curr Opin Psychiatry 2015; 28: 201-6.
93. Fernandes BS, Steiner J, Bernstein HG, et al. C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications. Mol Psychiatry 2015. doi: 10.1038/mp.2015.87.
94. Leza JC, García-Bueno B, Bioque M, et al. Inflammation in schizophrenia: A question of balance. Neurosci Biobehav Rev 2015; 55: 612-26.
95. Debnath M. Adaptive immunity in schizophrenia: Functional implications of T cells in the etiology, course and treatment. J Neuroimmune Pharmacol 2015; 10(4): 610-9.
96. Levite M. Dopamine and T cells: Receptors, direct and potent effects, Endogenous production and abnormalities in autoimmune, Neurological and psychiatric diseases. Acta Physiol (Oxf) 2015. doi: 10.1111/apha.12476.
97. Anders S, Kinney DK. Abnormal immune system development and function in schizophrenia helps reconcile diverse findings and suggests new treatment and prevention strategies. Brain Res 2015; 1617: 93-112.
98. Matsumoto A, Ohta N, Goto Y, Kashiwa Y, Yamamoto S, Fujino Y. Haloperidol suppresses murine dendritic cell maturation and priming of the T helper 1-type immune response. Anesth Analg 2015; 120: 895-902.
99. Ohi K, Hashimoto R, Ikeda M, et al. Glutamate networks implicate cognitive impairments in schizophrenia: Genome-wide association studies of 52 cognitive phenotypes. Schizophr Bull 2015; 41: 909-18.
100. Stringer S, Kahn RS, de Witte LD, Ophoff RA, Derks EM. Genetic liability for schizophrenia predicts risk of immune disorders. Schizophr Res 2014; 159: 347-52.
101. Severance EG, Gressitt KL, Alaedini A, et al. IgG dynamics of dietary antigens point to cerebrospinal fluid barrier or flow dysfunction in first-episode schizophrenia. Brain Behav Immun 2015; 44: 148-58.
102. Tomasik J, Rahmoune H, Guest PC, Bahn S. Neuroimmune biomarkers in schizophrenia. Schizophr Res 2014; pii: S0920-9964(14)00382-X. Available from: http://www.sciencedirect.com/science/article/pii/S092099641400382X
103. Gos T, Myint AM, Schiltz K, et al. Reduced microglial immunoreactivity for endogenous NMDA receptor agonist quinolinic acid in the hippocampus of schizophrenia patients. Brain Behav Immun 2014; 41: 59-64.
104. Ribeiro-Santos A, Lucio Teixeira A, Salgado JV. Evidence for an immune role on cognition in schizophrenia: a systematic review. Curr Neuropharmacol 2014; 12: 273-80.
105. Loftis JM, Huckans M, Morasco BJ. Neuroimmune mechanisms of cytokine-induced depression: current theories and novel treatment strategies. Neurobiol Dis 2010; 37: 519-33.
106. Miller AH. Depression and immunity: a role for T cells? Brain Behav Immun 2010; 24: 1-8.
107. Chu TT, Liu Y, Kemether E. Thalamic transcriptome screening in three psychiatric states. J Hum Genet 2009; 54: 665-75.
108. Clerici M, Arosio B, Mundo E, et al. Cytokine polymorphisms in the pathophysiology of mood disorders. CNS Spectr 2009; 14: 419-25.
109. Koido K, Eller T, Kingo K, et al. Interleukin 10 family gene polymorphisms are not associated with major depressive disorder and panic disorder phenotypes. J Psychiatr Res 2010; 44: 275-7.
110. Cerri AP, Arosio B, Viazzoli C, Confalonieri R, Teruzzi F, Annoni G. 308(G/A) TNF-alpha gene polymorphism and risk of depression late in the life. Arch Gerontol Geriatr 2009; 49 Suppl 1: 29-34.
111. Su S, Zhao J, Bremner JD, et al. Serotonin transporter gene, depressive symptoms, and interleukin-6. Circ Cardiovasc Genet 2009; 2: 614-20.
112. Matsunaga M, Isowa T, Murakami H, et al. Association of polymorphism in the human mu-opioid receptor OPRM1 gene with proinflammatory cytokine levels and health perception. Brain Behav Immun 2009; 23: 931-5.
113. Liao P, Soong TW. Ca(V)1.2 channelopathies: from arrhythmias to autism, bipolar disorder, and immunodeficiency. Pflugers Arch 2010; 460: 353-9.
114. Skaper SD, Debetto P, Giusti P. The P2X7 purinergic receptor: from physiology to neurological disorders. FASEB J 2010; 24: 337-45.
115. Manenschijn L, van den Akker EL, Lamberts SW, van Rossum EF. Clinical features associated with glucocorticoid receptor polymorphisms. An overview. Ann NY Acad Sci 2009; 1179: 179-98.
116. Chrousos GP, Kino T. Glucocorticoid signaling in the cell. Expanding clinical implications to complex human behavioral and somatic disorders. Ann NY Acad Sci 2009; 1179: 153-66.
117. Pace TW, Miller AH. Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann NY Acad Sci 2009; 1179: 86-105.
118. Kornhuber J, Reichel M, Tripal P, et al. The role of ceramide in major depressive disorder. Eur Arch Psychiatry Clin Neurosci 2009; 259 (Suppl 2): S199-204.
119. Dhabhar FS, Burke HM, Epel ES, et al. Low serum IL-10 concentrations and loss of regulatory association between IL-6 and IL-10 in adults with major depression. J Psychiatr Res 2009; 43: 962-9.
120. Christian LM, Franco A, Glaser R, Iams JD. Depressive symptoms are associated with elevated serum proinflammatory cytokines among pregnant women. Brain Behav Immun 2009; 23: 750-4.
121. Brietzke E, Stertz L, Fernandes BS, et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord 2009; 116: 214-7.
122. Hope S, Melle I, Aukrust P, et al. Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. Bipolar Disord 2009; 11: 726-34.
123. Gabbay V, Klein RG, Guttman LE, et al. A preliminary study of cytokines in suicidal and nonsuicidal adolescents with major depression. J Child Adolesc Psychopharmacol 2009; 19: 423-30.
124. Lindqvist D, Janelidze S, Hagell P, et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry 2009; 66: 287-92.
125. Ovaskainen Y, Koponen H, Jokelainen J, Keinänen-Kiukaanniemi S, Kumpusalo E, Vanhala M. Depressive symptomatology is associated with decreased interleukin-1 beta and increased interleukin-1 receptor antagonist levels in males. Psychiatry Res 2009; 167: 73-9.
126. Heinisch S, Kirby LG. Fractalkine/CX3CL1 enhances GABA synaptic activity at serotonin neurons in the rat dorsal raphe nucleus. Neuroscience 2009; 164: 1210-23.
127. Zhu J, Wei X, Liu J, Hu Y, Xu J. Interaction of glia activation and neurotransmission in hippocampus of neuropathic rats treated with mirtazapine. Exp Clin Psychopharmacol 2009; 17: 198-203.
128. O'Connor JC, André C, Wang Y, et al. Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2, 3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J Neurosci 2009; 29: 4200-9.
129. Miller AH, Timmie WP. Mechanisms of cytokine-induced behavioural changes: Psychoneuroimmunology at the translational interface. Brain Behav Immun 2009; 23: 149-58.
130. Hu F, Pace TW, Miller AH. Interferon-alpha inhibits glucocorticoid receptor-mediated gene transcription via STAT5 activation in mouse HT22 cells. Brain Behav Immun 2009; 23: 455-63.
131. Grippo AJ, Johnson AK. Stress, depression and cardiovascular dysregulation: a review of neurobiological mechanisms and the integration of research from preclinical disease models. Stress 2009; 12: 1-21.
132. Milior G, Lecours C, Samson L, et al. Fractalkine receptor deficiency impairs microglial and neuronal responsiveness to chronic stress. Brain Behav Immun 2015; pii: S0889-1591(15)00419-5. Available from: http://www.sciencedirect.com/science/article/pii/S0889159115004195
133. Wei J, Zhang M, Zhou J. Myeloid-derived suppressor cells in major depression patients suppress T-cell responses through the production of reactive oxygen species. Psychiatry Res 2015; 228(3): 695-701.
134. Toben C, Baune BT. An act of balance between adaptive and maladaptive immunity in depression: A role for T lymphocytes. J Neuroimmune Pharmacol 2015; 10(4): 595-609.
135. Kim YK, Na KS, Myint AM, Leonard BE. The role of proinflammatory cytokines in neuroinflammation, neurogenesis and the neuroendocrine system in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2015; 64: 277-84.
136. Postal M, Appenzeller S. The importance of cytokines and autoantibodies in depression. Autoimmun Rev 2015; 14: 30-5.
137. Maletic V, Raison C. Integrated neurobiology of bipolar disorder. Front Psychiatry 2014; 5: 98.
138. Guilloux JP, Bassi S, Ding Y, et al. Testing the predictive value of peripheral gene expression for nonremission following citalopram treatment for major depression. Neuropsychopharmacology 2015; 40: 701-10.
139. Zhan Y, Yang YT, You HM, et al. Plasma-based proteomics reveals lipid metabolic and immunoregulatory dysregulation in poststroke depression. Eur Psychiatry 2014; 29: 307-15.
140. Ding Y, Chang LC, Wang X, et al. Molecular and genetic characterization of depression: Overlap with other psychiatric disorders and aging. Mol Neuropsychiatry 2015; 1: 1-12.
141. Bechmann I. Failed central nervous system regeneration: A downside of immune privilege? Neuromol Med 2005; 7: 217-28.
142. Piehl F, Olsson T. Inflammation and susceptibility to neurodegeneration: The use of unbiased genetics to decipher critical regulatory pathways. Neuroscience 2009; 158: 1143-50.
143. Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG. Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener 2009; 4: 47.
144. Dheen ST, Kaur C, Ling EA. Microglial activation and its implications in the brain diseases. Curr Med Chem 2007; 14: 1189-97.
145. Griffiths M, Neal JW, Gasque P. Innate immunity and protective neuroinflammation: new emphasis on the role of neuroimmune regulatory proteins. Int Rev Neurobiol 2007; 82: 29-55.
146. Peng YP, Qiu YH, Lu JH, Wang JJ. Interleukin-6 protects cultured cerebellar granule neurons against glutamate-induced neurotoxicity. Neurosci Lett 2005; 374: 192-6.
147. Chakraborty S, Kaushik DK, Gupta M, Basu A. Inflammasome signaling at the heart of central nervous system pathology. J Neurosci Res 2010; 88: 1615-31.
148. Tweedie D, Sambamurti K, Greig NH. TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Curr Alzheimer Res 2007; 4: 378-85.
149. McCoy MK, Tansey MG. TNF signaling inhibition in the CNS: Implications for normal brain function and neurodegenerative disease. J Neuroinflam 2008; 5: 45.
150. Bajetto A, Bonavia R, Barbero S, Florio T, Schettini G. Chemokines and their receptors in the central nervous system. Front Neuroendocrinol 2001; 22: 147-84.
151. Cacabelos R, Cacabelos P, Torrellas C, Tellado I, Carril JC. Pharmacogenomics of Alzheimer's disease: novel therapeutic strategies for drug development. Methods Mol Biol 2014; 1175: 323-556.
152. Cacabelos R, Torrellas C, López-Muloz F. Epigenomics of Alzheimer’s disease. J Exp Med 2014; 6: 75-82.
153. Cacabelos R, Torrellas C. Epigenetic drug discovery for Alzheimer's disease. Expert Opin Drug Discov 2014; 9: 1059-86.
154. Cacabelos R. Molecular genetics of Alzheimer’s disease and aging. Meth Find Exper Clin Pharmacol 2005; 27 (Suppl A): 1-573.
155. Online Mendelian Inheritance in Man, OMIM® [Homepage on the Internet]. Baltimore, MD: McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University. Available from: http://omim.org/
156. Alzforum [homepage on the Internet]. Cambridge: Biomedical Research Forum. Available from: http: //www.alzforum.org/
157. Tan MG, Chua WT, Esiri MM, Smith AD, Vinters HV, Lai MK. Genome wide profiling of altered gene expression in the neocortex of Alzheimer's disease. J Neurosci Res 2010; 88: 1157-69.
158. Cacabelos R, Takeda M. Pharmacogenomics, nutrigenomics and future therapeutics in Alzheimer’s disease. Drugs Future 2006; 31 Suppl B: 5-146.
159. Cacabelos R. Pharmacogenomic biomarkers in neuropsychiatry: The path to personalized medicine in mental disorders. In: Ritsner MS, Ed. The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes. Netherlands: Springer 2009; pp. 3-63.
160. Cacabelos R. Pharmacogenomics and therapeutic strategies for dementia. Expert Rev Mol Diag 2009; 9: 567-611.
161. Cacabelos R. The application of functional genomics to Alzheimer’s disease. Pharmacogenomics 2003; 4: 597-621.
162. Cacabelos R. Pharmacogenomics and therapeutic prospects in Alzheimer’s disease. Exp Opin Pharmacother 2005; 6: 1967-87.
163. Cacabelos R. Pharmacogenomics, nutrigenomics and therapeutic optimization in Alzheimer’s disease. Aging Health 2005; 1: 303-48.
164. Cacabelos R, Fernández-Novoa L, Lombardi V, et al. Cerebrovascular risk factors in Alzheimer’s disease: Brain hemodynamics and pharmacogenomic implications. Neurol Res 2003; 25: 567-80.
165. Eikelenboom P, Veerhuis R, Scheper W, et al. The significance of neuroinflammation in understanding Alzheimer's disease. J Neural Transm 2006; 113: 1685-95.
166. Rossi D, Volterra A. Astrocytic dysfunction: insights on the role in neurodegeneration. Brain Res Bull 2009; 80: 224-32.
167. McGeer PL, McGeer EG. Local neuroinflammation and the progression of Alzheimer's disease. J Neurovirol 2002; 8: 529-38.
168. McGeer PL, McGeer EG. Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging 2001; 22: 799-809.
169. Bonifati DM, Kishore U. Role of complement in neurodegeneration and neuroinflammation. Mol Immunol 2007; 44: 999-1010.
170. Ager RR, Fonseca MI, Chu SH, et al. Microglial C5aR (CD88) expression correlates with amyloid-beta deposition in murine models of Alzheimer's disease. J Neurochem 2010; 113: 389-401.
171. Takata K, Hirata-Fukae C, Becker AG, et al. Deglycosylated antiamyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration. Eur J Neurosci 2007; 26: 2458-68.
172. Mehlhorn G, Hollborn M, Schliebs R. Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. Int J Dev Neurosci 2000; 18: 423-31.
173. Park KM, Yule DI, Bowers WJ. Impaired TNF-alpha control of IP3R-mediated Ca2+ release in Alzheimer's disease mouse neurons. Cell Signal 2010; 22: 519-26.
174. Passos GF, Figueiredo CP, Prediger RD, et al. Role of the macrophage inflammatory protein-1alpha/CC chemokine receptor 5 signaling pathway in the neuroinflammatory response and cognitive deficits induced by beta-amyloid peptide. Am J Pathol 2009; 175: 1586-97.
175. Calingasan NY, Erdely HA, Altar CA. Identification of CD40 ligand in Alzheimer's disease and in animal models of Alzheimer's disease and brain injury. Neurobiol Aging 2002; 23: 31-9.
176. Walker DG, Dalsing-Hernandez JE, Campbell NA, Lue LF. Decreased expression of CD200 and CD200 receptor in Alzheimer's disease: a potential mechanism leading to chronic inflammation. Exp Neurol 2009; 215: 5-19.
177. Kiyota T, Yamamoto M, Xiong H, et al. CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction. PLoS One 2009; 4: e6197.
178. Takenouchi T, Sekiyama K, Sekigawa A, et al. P2X7 receptor signaling pathway as a therapeutic target for neurodegenerative diseases. Arch Immunol Ther Exp (Warsz) 2010; 58: 91-6.
179. Hoppe JB, Frozza RL, Horn AP, et al. Amyloid-beta neurotoxicity in organotypic culture is attenuated by melatonin: involvement of GSK-3beta, tau and neuroinflammation. J Pineal Res 2010; 48: 230-8.
180. Streit WJ, Xue QS. Life and death of microglia. J Neuroimmune Pharmacol 2009; 4: 371-9.
181. Fang F, Lue LF, Yan S, et al. RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J 2010; 24: 1043-55.
182. Davenport CM, Sevastou IG, Hooper C, Pocock JM. Inhibiting p53 pathways in microglia attenuates microglial-evoked neurotoxicity following exposure to Alzheimer peptides. J Neurochem 2010; 112: 552-63.
183. Cimino PJ, Sokal I, Leverenz J, Fukui Y, Montine TJ. DOCK2 is a microglial specific regulator of central nervous system innate immunity found in normal and Alzheimer's disease brain. Am J Pathol 2009; 175: 1622-30.
184. Chakrabarty P, Jansen-West K, Beccard A, et al. Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J 2010; 24: 548-59.
185. Hein AM, Stasko MR, Matousek SB, et al. Sustained hippocampal IL-1beta overexpression impairs contextual and spatial memory in transgenic mice. Brain Behav Immun 2010; 24: 243-53.
186. Kraft R. STIM and ORAI proteins in the nervous system. Channels (Austin) 2015; 9(5): 245-52.
187. Ferreira AC, Dá Mesquita S, Sousa JC, et al. From the periphery to the brain: Lipocalin-2, a friend or foe? Prog Neurobiol 2015; 131: 120-36.
188. Deneka A, Korobeynikov V, Golemis EA. Embryonal Fynassociated substrate (EFS) and CASS4: The lesser-known CAS protein family members. Gene 2015; 570: 25-35.
189. Carrera I, Etcheverría I, Li Y, et al. Immunocytochemical characterization of Alzheimer disease hallmarks in APP/PS1 transgenic mice treated with a new anti-amyloid-vaccine. Biomed Res Int 2013; 2013: 709145.
190. Carrera I, Cacabelos R. Novel immunotherapeutic procedures for prevention of Alzheimer’s disease. Drug Des 2013; 2: 2.
191. Kudrna JJ, Ugen KE. Gene-based vaccines and immunotherapeutic strategies against neurodegenerative diseases: Potential utility and limitations. Hum Vaccin Immunother 2015; 11(8): 1921-6.
192. Mesquita SD, Ferreira AC, Gao F, et al. The choroid plexus transcriptome reveals changes in type I and II interferon responses in a mouse model of Alzheimer's disease. Brain Behav Immun 2015; 49: 280-92.
193. Song J, Lee JE. miR-155 is involved in Alzheimer's disease by regulating T lymphocyte function. Front Aging Neurosci 2015; 7: 61.
194. Lee KM, MacLean AG. New advances on glial activation in health and disease. World J Virol 2012; 4: 42-55.
195. Savage JC, Jay T, Goduni E, et al. Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer's disease. J Neurosci 2015; 35: 6532-43.
196. Xie L, Yang SH. Interaction of astrocytes and T cells in physiological and pathological conditions. Brain Res 2015; 1623: 63-3.
197. Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol 2015; 14: 388-405.
198. Watanabe T, Wada H. Histaminergic neuros: morphology and function. Boca Raton: CRC Press 1991.
199. Cacabelos R. Histaminergic regulation of the neuroendocrine system. In: Watanabe T, Wada H, Eds. Histaminergic Neurons: Morphology and Functions. Boca Raton: CRC Press1990; pp. 241-70.
200. Fernández-Novoa L, Cacabelos R. Histamine function in brain disorders. Behav Brain Res 2001; 124: 213-33.
201. Tiligada E, Zampeli E, Sander K, Stark H. Histamine H3 and H4 receptors as novel drug targets. Expert Opin Investig Drugs 2009; 18: 1519-31.
202. Baronio D, Gonchoroski T, Castro K, Zanatta G, Gottfried C, Riesgo R. Histaminergic system in brain disorders: lessons from the translational approach and future perspectives. Ann Gen Psychiatry 2014; 13: 34.
203. Cacabelos R, Yamatodani A, Fukui H, Takeda M, Nishimura T, Wada H. Age-and sex-related changes in histamine and H-1 receptors in the central nervous system following a long-term castration. Bull Jpn Neurochem Soc 1986; 25: 271-3.
204. Cacabelos R, Yamatodani A, Fukui H, et al. Nature of histaminergic neuromodulation of the corticotropinergic system. Biogenic Amines 1985; 3: 9-19.
205. Cacabelos R, Yamatodani A, Fukui H, et al. Time-and dosedependent responses of brain histamine to intracerebroventricular and intraperitoneal administrations of growth hormone-releasing factor (GRF1-44). Tohoku J Exp Med 1987; 151: 429-42.
206. Cacabelos R, Yamatodani A, Niigawa H, Harigmchi S, Nishimura T, Wada H. Histaminergic neuromodulation of the release of vasopressin. Neuroendocrinology 1987; 45: 368-75.
207. Cacabelos R, Fernández-Novoa L, Franco-Maside A, Álvarez XA. Neuroimmune function of brain histamine: implications for neurotrophic activity and neurotoxicity. Ann Psychiatry 1992; 3: 147-200.
208. Cacabelos R, Álvarez XA, Franco A, Fernández-Novoa L. Doseand time-dependent effects of histamine on hypothalamic levels of interleukin-1β in rats. Agents Actions 1993; 38: C260-2.
209. Fernández-Novoa L, Franco-Maside A, Álvarez XA, Cacabelos R. Effects of histamine and alpha-fluoromethylhistidine on brain tumor necrosis factor levels in rats. Inflamm Res 1995; 44: 55-7.
210. Cacabelos R, Yamatodani A, Niigawa H, et al. Brain histamine in Alzheimers disease. Meth Find Exp Clin Pharmacol 1989; 11: 353-60.
211. Cacabelos R, Álvarez XA, Fernández-Novoa L, et al. Brain interleukin-1β in Alzheimers disease and vascular dementia. Meth Find Exp Clin Pharmacol 1994; 16: 141-51.
212. Cacabelos R, Franco-Maside A, Álvarez XA. Interleukin-l in Alzheimer s disease and multi-infarct dementia: Neuropsychological correlations. Meth Find Exp Clin Pharmacol 1991; 13: 703-8.
213. Álvarez XA, Franco A, Fernández-Novoa L, Cacabelos R. Blood levels of histamine, IL-lβ, and TNF-α in patients with mild to moderate Alzheimer disease. Mol Chem Neuropathol 1996; 29: 237-52.
214. Cacabelos R, Álvarez XA, Franco A, Fernández-Novoa L, Caamaño J, Valle-lnclán F. Therapeutic effects of CDP-choline in Alzheimers disease and multi-infarct dementia: psychometric assessment and immune function. Ann Psychiatry 1992; 3: 233-45.
215. Cacabelos R, Álvarez XA, Franco-Maside A, Fernández-Novoa L, Caamaño J. Effect of CDP-choline on cognition and immune function in Alzheimers disease and multi-infarct dementia. Ann New York Acad Sci 1993; 695: 321-3.
216. Fernández-Novoa L, Álvarez XA, Franco-Maside A, Caamaño J, Cacabelos R. CDP-choline-induced blood histamine changes in Alzheimers disease. Meth Find Exp Clin Pharmacol 1994; 16: 279-84.
217. Álvarez XA, Franco A, Fernández-Novoa L, Cacabelos R. Effects of anapsos on behavior and brain cytokines in rats. Ann Psychiatry 1992; 3: 329-41.
218. Álvarez XA, Miguel-Hidalgo JJ, Fernández-Novoa L, Díaz J, Sempere JM, Cacabelos R. Anapsos: Neuroimmunotrophic treatment in Alzheimers disease and neurodegenerative disorders. CNS Drug Rev 1997; 3: 181-206.
219. Fernández-Novoa L, Álvarez XA, Franco A, Caamaño J, Cacabelos R. Histamine-induced interleukin-1 changes in the rat hypothalamus. Meth Find Exp Clin Pharmacol 1993; 15: 735-41.
220. Maneiro E, Lombardi VRM, Lagares R, Cacabelos R. An experimental model to study the cytotoxic effects induced by β-amyloid, histamine, LPS and serum from Alzheimer patients on rat cultured endothelial cells. Meth Find Exp Clin Pharmacol 1997; 19: 5-12.
221. Lombardi VRM, Garcia M, Cacabelos R. APOE-Induced microglial activation: An in vitro assay to screen sera from Alzheimers disease patients and novel therapeutic compounds. Meth Find Exp Clin Pharmacol 1998; 20: 377-86.
222. Lombardi VRM, García M, Cacabelos R. Microglial activation induced by factor(s) contained in sera from Alzheimer-related ApoE genotypes. J Neurosci Res 1998; 54: 539-53.
223. Lombardi VRM, Fernández-Novoa L, Etcheverría I, Seoane S, Cacabelos R. Association between APOE-4 allele and increased expression of CD95 on T cells from patients with Alzheimer’s disease. Meth Find Exp Clin Pharmacol 2004; 26: 523-29.
224. Shan L, Bao AM, Swaab DF. The human histaminergic system in neuropsychiatric disorders. Trends Neurosci 2015; 38: 167-77.
225. Haig GM, Pritchett Y, Meier A, et al. A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia. J Alzheimers Dis 2014; 42: 959-71.
226. Grove RA, Harrington CM, Mahler A, et al. A randomized, doubleblind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-tomoderate Alzheimer's disease. Curr Alzheimer Res 2014; 11: 47-58.
227. Kanerva K, Lappalainen J, Mäkitie LT, Virolainen S, Kovanen PT, Andersson LC. Expression of antizyme inhibitor 2 in mast cells and role of polyamines as selective regulators of serotonin secretion. PLoS One 2009; 4: e6858.
228. Cacabelos R. Histaminergic system: Neuroendocrine function of brain histamine. Meth Find Exp Clin Pharmacol 1990; 12: 341-76.
229. Nautiyal KM, Ribeiro AC, Pfaff DW, Silver R. Brain mast cells link the immune system to anxiety-like behavior. Proc Natl Acad Sci USA 2008; 105: 18053-7.
230. Sriskantharajah S, Ley SC. Turning off inflammation signaling. Science 327: 1093-4.
231. Shembade N, Ma A, Harhaj EW. Inhibition of NF-αB signaling by A20 through disruption of ubiquitin enzyme complexes. Science 2010; 27: 1135-9.
232. Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010; 464: 104-7.
233. Xu J, Chi F, Guo T, et al. NOTCH reprograms mitochondrial metabolism for proinflammatory macrophage activation. J Clin Invest 2015; 125: 1579-90.
234. Yin Y, Li X, Sha X, et al. Early hyperlipidemia promotes endothelial activation via a caspase-1-sirtuin 1 pathway. Arterioscler Thromb Vasc Biol 2015; 35: 804-16.
235. Qiu LQ, Lai WS, Bradbury A, Zeldin DC, Blackshear PJ. Tristetraprolin (TTP) coordinately regulates primary and secondary cellular responses to proinflammatory stimuli. J Leukoc Biol 2015; 97: 723-36.
236. Naegelen I, Plançon S, Nicot N, et al. An essential role of syntaxin 3 protein for granule exocytosis and secretion of IL-1α, IL-1β, IL-12b, and CCL4 from differentiated HL-60 cells. J Leukoc Biol 2015; 97: 557-71.
237. Yang JH, Kim KM, Kim MG, et al. Role of sestrin2 in the regulation of proinflammatory signaling in macrophages. Free Radic Biol Med 2015; 78: 156-67.
238. Chen Y, Zhang J, Zhang B, et al. Targeting insulin signaling for the treatment of Alzheimer's disease. Curr Top Med Chem 2016; 16(5): 485-92.
239. Hu R, Zhang M, Chen H, et al. Cross-Seeding interaction between β-amyloid and human islet amyloid polypeptide. ACS Chem Neurosci 2015; 6(10): 1759-68.